Poster

Identification And Risk Mitigation Of A Critical Process Parameter During Antibody Process Scale-Up

By Christa Short, Midge Bonzon, Jonathan Mitschelen, Upstream Process Development, R&D Services

iStock-899692840-cleanroom

This poster is a version of slides presented at PEGS Summit in Boston, MA, in the session of "Scaling Up and Down Strategies for Protein Production."

The case study presented involved the production of a Phase 1 clinical trial material at a100 L scale with limited process development prior to cGMP production and productivity of <1 g/L, below industry standard. A scale-up to 1,000 L was planned for a Phase 2 clinical supply, with an initial 1,000 L batch being successful with similar yield to 100 L batches. The second 1,000 L batch failed to reach normal cell density, and yield was much lower than normal. Risk mitigation for a third batch included rigorous data review and the implementation of a process control strategy.

Topics include:

  • Impact on Manufacturing
  • Company Strategies
  • Regulatory Considerations
  • mAb Process Flowchart
  • mAb Production Process
  • Process Performance History
  • Glutamate Issues & Process Range
  • Process Change Options
  • Final Change and Justification
  • Results
  • Conclusions

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: